Expression of a 65 kDa oncofetal protein in human prostatic carcinoma

Margaret Hanausek, Zbigniew Walaszek, Terri M. King, Christopher I. Amos

Research output: Contribution to journalArticlepeer-review

Abstract

The concentration of a novel 65 kDa oncofetal protein, p65, was measured in the sera of patients with prostatic malignancies using an enzyme-linked immunosorbent assay. The prostate cancer sera were positive for p65 in 40 out of 59 cases (68%), while only 7 of 79 normal sera (9%) and 12 of 61 sera from patients with benign diseases (20%) were positive. The detection system had an overall sensitivity of 68% and a specificity of 86%. Elevated p65 levels correlated positively with the pathologic stages of the prostate cancer. Using this marker in concert with PSA may increase our ability to evaluate treatment response and aid in early detection of prostate cancer.

Original languageEnglish (US)
Pages (from-to)1387-1392
Number of pages6
JournalOncology reports
Volume10
Issue number5
DOIs
StatePublished - Sep 2003
Externally publishedYes

Keywords

  • Oncofetal protein p65
  • Prostate cancer
  • Tumor markers

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint

Dive into the research topics of 'Expression of a 65 kDa oncofetal protein in human prostatic carcinoma'. Together they form a unique fingerprint.

Cite this